Negative impact of skeletal muscle loss after systemic chemotherapy in patients with unresectable colorectal cancer

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Miyamoto, Yuji ^a   Baba, Yoshifumi ^a   Sakamoto, Yasuo ^a   Ohuchi, Mayuko ^a   Tokunaga, Ryuma ^a   Kurashige, Junji ^a   Hiyoshi, Yukiharu ^a   Iwagami, Shiro ^a   Yoshida, Naoya ^a   Watanabe, Masayuki ^b   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IRINOTECAN; OXALIPLATIN;

AGE DISTRIBUTION; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE MASS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SARCOPENIA; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT OUTCOME; COLORECTAL NEOPLASMS; COMPLICATION; PROGNOSIS;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; PROGNOSIS; SARCOPENIA;

EID: 84935442204     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129742     Document Type: Article

References (23)

1. Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H. Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2014; 44:388-396. doi: 10.1093/jjco/hyu003 PMID: 24503029
2. Meulenbeld HJ, van Steenbergen LN, Janssen-Heijnen ML, Lemmens VE, Creemers GJ. Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004. Ann Oncol 2008; 19:1600-1604. doi: 10.1093/annonc/mdn176 PMID: 18467312
3. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27:3677-3683. doi: 10.1200/JCO.2008.20.5278 PMID: 19470929
4. Lieffers JR, Bathe OF, Fassbender K, Winget M, Baracos VE. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer 2012; 107:931-936. doi: 10.1038/bjc.2012.350 PMID: 22871883
5. Peng PD, van Vledder MG, Tsai S, de Jong MC, Makary M, Ng J, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford) 2011; 13:439-446. doi: 10.1111/j.1477-2574.2011.00301.x PMID: 21689226
6. Hasselager R, Gogenur I. Core muscle size assessed by perioperative abdominal CT scan is related to mortality, postoperative complications, and hospitalization after major abdominal surgery: a systematic review. Langenbecks Arch Surg 2014; 399:287-295. doi: 10.1007/s00423-014-1174-x PMID: 24535479
7. Barret M, Antoun S, Dalban C, Malka D, Mansourbakht T, Zaanan A, et. al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer 2014; 66:583-589. doi: 10. 1080/01635581.2014.894103 PMID: 24707897
8. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 2007; 13:3264-3268. PMID: 17545532
9. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15:2920-2926. doi: 10.1158/1078-0432.CCR-08-2242 PMID: 19351764
10. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008; 9:629-635. doi: 10.1016/S1470-2045(08)70153-0 PMID: 18539529
11. van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans JN. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg 2012; 99:550-557. doi: 10.1002/bjs.7823 PMID: 22246799
12. Iritani S, Imai K, Takai K, Hanai T, Ideta T, Miyazaki T, et al. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J Gastroenterol doi: 10.1007/s00535-014-0964-92014 [Online May 10, 2014].
13. Voron T, Tselikas L, Pietrasz D, Pigneur F, Laurent A, Compagnon P, et. al. Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma. Ann Surg doi: 10.1097/ SLA.0000000000000743 [Online June 19, 2014].
14. Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol 2011; 18:3579-3585. doi: 10.1245/s10434-011-1976-9 PMID: 21822551
15. Collins J, Noble S, Chester J, Coles B, Byrne A. The assessment and impact of sarcopenia in lung cancer: a systematic literature review. BMJ Open 2014; 4:e003697. doi: 10.1136/bmjopen-2013-003697 PMID: 24384894
16. Yip C, Goh V, Davies A, Gossage J, Mitchell-Hay R, Hynes O, et al. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur Radiol 2014; 24:998-1005. doi: 10.1007/s00330-014-3110-4 PMID: 24535076
17. Kovarik M, Hronek M, Zadak Z. Clinically relevant determinants of body composition, function and nutritional status as mortality predictors in lung cancer patients. Lung Cancer 2014; 84:1-6. doi: 10.1016/j. lungcan.2014.01.020 PMID: 24560334
18. Segal MR. Regression trees for censored data. Biometrics 1988; 44:35-4835e48.
19. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009; 15:6973-6979. doi: 10. 1158/1078-0432.CCR-09-1525 PMID: 19887488
20. Antoun S, Borget I, Lanoy E. Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Curr Opin Support Palliat Care 2013; 7:383-389. doi: 10.1097/SPC.0000000000000011 PMID: 24189893
21. Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 2011; 62:265-279. doi: 10.1146/annurev-med-061509-131248 PMID: 20731602
22. Stene GB, Helbostad JL, Amundsen T, Sorhaug S, Hjelde H, Kaasa S, et al. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol 1-9 2014;:.
23. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147:755-763. PMID: 9554417